Elephas Names Ann Leonard Director of Quality
Madison, WI, October 12, 2020 -- Elephas Biosciences Corporation(Elephas), a live tumor imaging company developing novel cancer diagnostic solutions, announced today Ann Leonard has joined the company as Director of Quality.
Leonard is an accomplished expert with broad experience managing quality, regulatory, and business requirements for the medical device, pharmaceutical, and biotechnology industries. Leonard will be responsible for developing, managing, and improving quality management system core processes compliant with ISO 9001, ISO 13485, and FDA QSR for the company.
"Investing in leadership to build a quality department at this early stage is critically important,” said Maneesh Arora, founder and CEO of Elephas. "Ann’s impressive track record, paired with her experience across all areas of quality and compliance, will be important drivers of our platform development in the coming years”.
An ASQ Certified Manager of Quality & Organizational Excellence, Leonard started her career at Promega before joining Mueller Sports Medicine as a Director of Quality Systems & Material Quality. Most recently, she served as a Global Quality Manager at Thermo Fisher Scientific.
"Elephas’ dedicated team, and mission develop innovative solutions for cancer patients is why I am so excited to join,” said Leonard. “And in order to make the extraordinary impact that this platform is capable of, it’s key that all quality, compliance, and certifications are carefully planned from the beginning”
Leonard earned her bachelor’s degree in animal science from Iowa State University, an MBA in quality management from Upper Iowa University, and a graduate certificate in biopharmaceutical international regulatory affairs from Northeastern University.
Disruption in healthcare is being accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision making and accelerate drug development. We plan to use the power of our platform to deliver a global solution that can revolutionize cancer treatment for every individual. To learn more, visit us at www.elephas.com or follow us on LinkedIn.
CGLife on Behalf of Elephas